Hematological Disorders Resource Center

Click on the subcategory below to find drug monographs for that particular area.

Imbruvica: Expanded Use

The FDA has approved the expanded use of Imbruvica to treat patients with chronic lymphocytic leukemia who carry a deletion in chromosome 17.

Lymphoma Treatment & Sperm Damage

Lymphoma treatment has damaging effects on spermatogenesis but, in most patients, sperm production recovers within two years post-treatment.

Stem Cells Transplants in SCID

For children with severe combined immunodeficiency, hematopoietic-cell transplantation from matched sibling donors shows excellent survival.

Octagam 10% Approved

The FDA has approved Octagam 10% liquid preparation for the treatment of adults with chronic immune thrombocytopenic purpura (ITP).

Hem B Prophylaxis: Positive Results

Pfizer announced positive results of a Phase 3 study comparing BeneFIX Coagulation Factor IX (Recombinant) to on-demand treatment.

Zydelig Approved for Blood Cancer

The FDA has approved Zydelig (idelalisib) in combination with rituximab for patients with relapsed chronic lymphocytic leukemia.

Hematological Reference Values

Review this chart on 'Hematological Reference Values' for quick information when you need it.

New Drug Product: Alprolix

Prevention and control of bleeding in hemophilia B.

Featured courses from mycme

The Brigham Board Review in Hematology and OncologyExternal web site

The Brigham Board Review in Hematology and Oncology offers expert preparation for your ABIM subspecialty ...

CME 42.00 Credits

Vertebroplasty is effective for managing myelomatous VCFsExternal web site

Nurse awareness of this treatment option and the patient selection criteria may be a significant ...

CE 0.60 Credits

Transformative Changes in the Management of Multiple MyelomaExternal web site

This symposium will address practical applications of an individualized approach to management of patients with ...

CME 0.50 Credits

Sign Up for Free e-newsletters